AIM The International Paediatric Multiple Sclerosis Study Group (IPMSSG) has proposed criteria for acute disseminated encephalomyelitis (ADEM) not evaluated in clinical practice. Our objective was to assess epidemiological implications of the IPMSSG criteria for ADEM in a cohort study using prospectively collected data.
Acute disseminated encephalomyelitis (ADEM) is an immune-mediated inflammatory disorder of the central nervous system. It is typically transitory and characterized by encephalopathy and multifocal neurological deficits. 1 A hallmark is abnormal magnetic resonance imaging (MRI) showing large, poorly demarcated white-matter lesions. 1 Studies have reported that 5 per cent to 29 per cent of paediatric ADEM progress to multiple sclerosis with a follow-up ranging from 6 months to 6 years 7 months. [2] [3] [4] [5] [6] [7] [8] However, differences in methodology complicate study comparisons, particularly regarding whether an ADEM diagnosis requires encephalopathy and polyfocal neurological deficits at onset; whether a subsequent diagnosis of multiple sclerosis involves one or two non-encephalopathic demyelinating events; and whether multiple sclerosis can be diagnosed in a child who has ADEM but no further clinical events, and subsequent MRI studies show new abnormalities that meet the radiologic criteria for dissemination in space and time. Further, referral bias may overestimate the reported percentage of ADEM progressing to multiple sclerosis, mainly if the study sample is not population-based. Evidence-based knowledge of the prognosis after an episode of ADEM is crucial to tailor follow-up and counsel parents satisfactorily. Therefore, because of the need for new and more accurate ADEM criteria, the International Paediatric Multiple Sclerosis Study Group (IPMSSG) proposed criteria for ADEM and subsequent multiple sclerosis for clinical and research purposes. 1, 9, 10 To assess the implications of the IPMSSG criteria, we undertook a nationwide population-based cohort study of children and adolescents (<18y) diagnosed with ADEM in Denmark, from 1st January 2008 to 31st December 2015. As the IPMSSG criteria are not routinely used in clinical practice in Denmark, we defined ADEM based on criteria usually used by Danish clinicians treating children with demyelinating disorders and subsequently stratified these children according to the IPMSSG criteria. Our aim was to examine how the IPMSSG criteria would impact the incidence of ADEM, and the clinical practice regarding onset symptoms, paraclinical findings, treatment, prognosis, and the risk of relapse or disease progression to multiple sclerosis.
METHODS

Data sources
The National Patient Register (NPR) contains nationwide information on all patients admitted to somatic wards in Denmark since 1977. 11 This includes demographic characteristics (e.g. age, sex), administrative details (e.g. date of admission, hospital), and diagnoses according to the International Classification of Diseases version 10 (ICD-10). Internationally, the NPR is considered one of the most comprehensive of its kind.
11
Demographical data (mortality and migration status) were obtained by linking patients with the Civil Registration System using their unique personal identification number available to all Danish residents. 12 
Definition of the data set
The source population for this cohort study was all inhabitants of Denmark younger than 18 years of age at onset (approximately 1.2 million), observed from 1st January 2008 to 31st December 2015. This period was chosen because all medical records were available in electronic form.
Two senior paediatric neurologists (APB and PVU) and a fellow neurologist (MSB) provided diagnosis codes covering virtually all potential cases of ADEM in Denmark. This yielded the following diagnoses (ICD-10 codes in brackets): optic neuritis (H46), transverse myelitis (G37.3), neuromyelitis optica spectrum disorder (G36.0), and other acute demyelination (G04.0, G04.8, G04.9, G36.8, G36.9, G37.8, G37.9). Children with ICD-10 codes used for encephalitis caused by specific infectious agents, such as zoster (B02.0), varicella (B01.1), and measles (B05.0), would not have been captured in our study design, but we did include unspecified encephalitis (G04.0, G04.8, G04.9). We (MSB and APB) subsequently reviewed all medical records to find those diagnosed with ADEM and critically reviewed the diagnosis to ensure that ADEM was the final and most likely clinical diagnosis (referred to as 'Clinical ADEM'). We believe that Clinical ADEM covers children who are diagnosed with ADEM in a clinical setting because the evaluating physicians judged that that ADEM was the most relevant diagnosis. The review committee (MSB and APB) confirmed this based on: (1) age at onset; (2) past medical history; (3) acute/subacute symptom onset; (4) symptomatology with encephalopathy or focal neurological deficit; (5) symptom evolution/regression in the months after the event; (6) laboratory findings, including cerebrospinal fluid (CSF) findings; (7) abnormal MRI findings. Children with Clinical ADEM had at least one neurological symptom (encephalopathy, motor or sensory deficit, headache, photo-or phonophobia, ataxia or problems with gait or balance, speech problems, visual reduction, urinary retention, or seizures) including an abnormal MRI. However, encephalopathy or multifocal neurological deficits were not a prerequisite for the diagnosis of Clinical ADEM. We then compared this ADEM cohort with the IPMSSG criteria of ADEM. 1, 10 We collected clinical and paraclinical data on all patients. We followed patients to the date of the medicalrecord review (June-August 2016) to monitor the clinical and paraclinical evolution. The date of last follow-up was set to 1st June 2016.
Definition of diagnoses ADEM
The IPMSSG defines ADEM as (1) a first polyfocal, clinical central nervous system event with presumed inflammatory demyelinating cause; (2) encephalopathy not explained by fever, systemic illness, or postictal symptoms; (3) no new clinical and MRI findings emerge 3 months or more after the onset; (4) brain MRI is abnormal during the acute (3mo) phase with diffuse, poorly demarcated, large (>1-2cm) lesions predominantly involving the cerebral white matter. 1, 10 Among Clinical ADEM, the majority did not fulfil the aforementioned diagnostic criteria for ADEM. Therefore, we defined a subgroup of patients ('IPMSSG ADEM') who fulfilled the IPMSSG criteria of ADEM. We defined 'encephalopathy' as alteration in consciousness (excessive fatigue or reduced consciousness) or behavioural change (e.g. confusion) unrelated to seizures, fever, or postictal symptoms. Moreover, we categorized patients into the following categories according to their neurological deficits: longtract motor deficits, oculomotor deficits, sensory deficits, visual problems, ataxia/gait/balance problems, seizure, and unconsciousness. We defined polyfocal neurological deficits as symptoms implicating two or more of these deficits (except unconsciousness).
Patient data Clinical data
From the clinical records, we collected data at presentation on age at onset, sex, medical history, antecedent vaccination (<4wks), and onset symptoms.
Patients were categorized on hospital admission into infection/fever, headache, photo-or phonophobia, seizures, What this paper adds
• The incidence of paediatric acute disseminated encephalomyelitis (ADEM) was 0.54 per 100 000 person-years in children younger than 18 years.
• Only 35 per cent of children with ADEM fulfilled the International Paediatric Study Group consensus criteria.
• ADEM in clinical practice was primarily based on magnetic resonance imaging findings.
• Paediatric neurologists diagnosed ADEM in the absence of encephalopathy.
• None of the children with ADEM progressed to multiple sclerosis/multiphasic ADEM during follow-up.
oculomotor deficits, long-tract motor deficits, sensory deficits, visual reduction, gait problems/ataxia, urinary retention, speech problems, and encephalopathy.
On follow-up, we classified patients into three levels of remission of the initial ADEM symptoms: complete, partial, or no remission. Patients with partial remission had neurological or cognitive problems, or excessive fatigue.
CSF data
We collected data on CSF during the acute phase of the ADEM episode including leucocytes, protein, glucose, immunoglobulin G index, oligoclonal bands, and herpes zoster or simplex virus.
MRI data
We collected data on all MRIs. We had no access to the MRI for review; instead, we relied on the radiological report or the medical records. We retrieved information on lesion site and gadolinium-contrast enhancement. Further, we listed the total number of MRIs for each patient, and we chose the most recent follow-up MRI to assign patients to the following groups according to the resolution of the white-matter lesions: 'complete', 'partial', 'unchanged', or 'progression'. We calculated a follow-up time from the first MRI to the most recent for those without complete remission.
Statistical analysis
The mid-year Danish population size by sex, age, and calendar time was derived from Statistics Denmark. 13 In the age group younger than 18 years, 90.5 per cent were Caucasian. Age-and sex-specific incidence rates and the 95 per cent confidence interval (CI) were calculated by assuming Poisson distribution. The assumptions for the Poisson regression were met because (1) observations were independent, (2) the number of children at risk of ADEM was large (approximately 1.2 million children), and (3) the probability of acquiring ADEM was small. To safeguard, we allowed for overdispersion because the probability of acquiring ADEM may be influenced by parameters not included in our analysis.
For comparisons, we divided Clinical ADEM (n=52) into two subgroups based on fulfilment of the IPMSSG criteria for ADEM: IPMSSG ADEM (n=18), and 'NON-IPMSSG ADEM' (n=34). Comparisons were made between these two subgroups using the t-test for quantitative data and Fisher's exact test for categorical data. Analyses were performed using SAS, version 9.4 (SAS Institute Inc., Cary, NC, USA).
Ethics
The study was approved by the Danish Data Protection Agency at Copenhagen University Hospital (case number 30-1423/03567) and the Danish Health Data Authority (case number 00001716). The Danish Health and Medicines Authority waived the requirement to obtain patient informed consent to access medical records (case number 3-3013-896/1). The chief physician of the Danish paediatric or neurological departments approved access to patient records from their hospital.
RESULTS
Between 2008 and 2015, we identified 415 patients aged younger than 18 years with one of the aforementioned diagnostic codes in the NPR. After reviewing all medical records, we identified 52 patients diagnosed with ADEM (Clinical ADEM). However, when stratifying by encephalopathy and polyfocal neurological deficits, only 18 (35%) fulfilled the IPMSSG criteria for ADEM (Fig. 1) .
The majority of excluded patients had multiple sclerosis (n=61), isolated optic neuritis (n=46), transverse myelitis (n=16), neuromyelitis optica spectrum disorder (n=5), clinically isolated syndrome with dissemination in space but not dissemination in time (n=4), radiological isolated syndrome (n=1), encephalitis (n=71), or epilepsy (n=23). Children with multiple sclerosis were older than children with ADEM at onset (median age of multiple sclerosis: 16y 4mo; range: 9y 2mo-17y 10mo), and none of the 61 children with multiple sclerosis was considered to have ADEM at onset. Six children were excluded because the onset was outside the study period or because they were foreign residents (Fig. 1) . Clinical and MRI data regarding the four children with clinically isolated syndrome with dissemination in space on MRI including a statement for not classifying these children as ADEM are given in Table I .
Clinical features at onset
The median age at onset in Clinical ADEM was 5 years 6 months (9mo-17y 2mo) and 62 per cent were male. Eight per cent had previous neurological or psychiatric disease (one with transverse myelitis) and four per cent had received a vaccine in the Danish childhood vaccination program within 4 weeks before ADEM (Table II) .
At onset, 79 per cent of children had either fever or an infection. The most common neurological deficits were gait problems and ataxia (42%), long-tract motor deficits (35%), and speech problems (22%); 50 per cent had polyfocal neurological deficits and 71 per cent had encephalopathy.
IPMSSG ADEM (compared to NON-IPMSSG ADEM) were younger at onset (median: 3y 10mo vs 8y 3mo), and more often presented with gait problems (67% vs 29%), focal neurological symptoms (100% vs 79%), or encephalopathy (100% vs 56%), but less often presented with headache (6% vs 56%).
Incidence rates of ADEM
The incidence rate of Clinical ADEM in children younger than 18 years was 0.54 per 100 000 person-years (95% CI: 0.39-0.75) for both sexes; for males: 0.65 (0.42-1.00), and for females: 0.43 (0.25-0.74). The incidence rate of IPMSSG ADEM was 0.19 per 100 000 (95% CI: 0.10-0.34).
The incidence of ADEM peaked in children aged 2 years and 3 years. This age distribution was seen in all our ADEM categories. Notably, the median age at onset (5y 6mo) better reflects the incidence pattern than does the mean age (7y 2mo) (Fig. 2) .
Clinical features at follow-up
The median clinical follow-up was 4 years 6 months (range 10mo-8y 3mo), and the median age at follow-up end was 10 years 9 months (range 2y-24y 3mo). Only nine of the 52 children in Clinical ADEM were followed for less than 2 years, and one child was followed for less than 1 year (followed for 10mo). All patients in the Clinical ADEM group showed some remission of their initial symptoms with 67 per cent having complete remission and 33 per cent having partial remission (Table II) . None experienced a further relapse of ADEM or died.
Conversely, patients with IPMSSG ADEM were younger at follow-up end (median age: 8y 3mo vs 12y 2mo) and fewer had complete remission of their initial symptoms (56% vs 73%).
ADEM and subsequent progression to multiple sclerosis
According to the IPMSSG criteria, a patient with ADEM is subsequently diagnosed with multiple sclerosis when he or she has a second clinical event meeting the following three requirements. The event (1) is non-encephalopathic; (2) occurs 3 or more months after the incident neurologic illness; and (3) is associated with new MRI findings consistent with revised radiologic criteria for 'dissemination in space'. 1 When applying these criteria, no child with ADEM progressed to multiple sclerosis. However, using the current criteria we found it challenging to categorize the following four children with ADEM: the first child was an 8-year-old male presenting with encephalopathy, diplopia, paraplegia, and urinary retention. His CSF revealed pleocytosis (61 leucocytes), increased protein (0.69g/L), negative oligoclonal bands, and negative aquaporin-4 antibodies, but positive myelin oligodendrocyte glycoprotein antibodies. His MRI showed white-matter lesions in the cerebrum, brain stem, and spinal cord, but no black holes or periventricular lesions. Two months later he experienced optic neuritis. The second patient was a 6-year-old female presenting with gait and speech problems including encephalopathy. Her CSF was normal apart from slight pleocytosis (8 leucocytes); her MRI showed bilateral, supra-and infratentorial contrast-enhancing white-matter lesions. Her initial symptoms partially regressed, and she never experienced a new clinical episode of neurological symptoms; however, her follow-up MRIs revealed an accrual of demyelination, including periventricular and subcortical white-matter lesions, and black holes. The third child was an 8-year-old male who presented with encephalopathic ADEM. His medical history was notable for transverse myelitis at 5 years of age. The fourth child experienced two non-encephalopathic clinical episodes both occurring after an infection: the first episode included optic neuritis and gait disorder at age 3 years. Her CSF revealed mild pleocytosis and she had negative aquaporin-4 antibodies. Her MRI showed T2 hyperintense optic nerve and lesions in the basal ganglia but no contrast enhancement. Her symptoms regressed and 9 months later she experienced gait disorder including new periventricular and infratentorial T2 lesions.
CSF
In Clinical ADEM, the CSF analysis revealed pleocytosis (81%) and increased protein in 24% (Table III) . Immunoglobulin G index was increased in 32 per cent whereas only nine per cent had oligoclonal bands. Ten children (19%) were negative for aquaporin-4 antibodies and one child had a positive test. Two children (4%) were tested for myelin oligodendrocyte glycoprotein and one test was positive. IPMSSG ADEM more often had increased immunoglobulin G index (50% vs 25%) and oligoclonal bands (20% vs 6%) compared with NON-IPMSSG ADEM, although differences were not statistically significant.
MRI
We obtained the complete radiological report of the initial MRI in 59 per cent of patients; for the remaining cases, information was retrieved from the medical records.
At onset, virtually all patients with Clinical ADEM showed white-matter lesions suggestive of ADEM. Lesions were often bilateral (87%), and half of the patients showed both supra-and infratentorial lesions (50%), as well as lesions in the thalamus or other basal ganglia (50%). Lesions that were periventricular, perpendicular to the corpus callosum, or black holes were rarely described in the radiological reports. Among children who underwent MRI of the spine (31%) showed white-matter lesions in the spinal cord (75%); 25 per cent had gadolinium enhancement in the central nervous system. The same pattern was seen in IPMSSG ADEM (Table III) .
At follow-up, the median number of MRIs was three (1-11). In the Clinical ADEM group, 10 per cent had no follow-up MRI. Complete resolution was seen on the follow-up MRI in 45 per cent. In patients showing partial resolution (51%) or no resolution (4%), the time between the first and most recent MRI was 8 months (range: 7d-8y 2mo). However, fewer patients in the IPMSSG ADEM group showed complete resolution (25% vs 55%) on follow-up MRI, although the median MRI follow-up was shorter (7mo vs 1y 2mo).
Treatment
In Clinical ADEM, 98 per cent of patients received intravenous methylprednisolone, followed by oral prednisone for 4 to 5 weeks (data not shown). Ten per cent received intravenous immunoglobulins, and 4 per cent received plasmapheresis. The same trends were seen in IPMSSG ADEM. During follow-up, two patients (4%) transiently received disease modifying drugs (interferon beta-1a).
DISCUSSION
Based on 52 cases, we found that the incidence of children (<18y) diagnosed with ADEM was 0.54 per 100 000 person-years (95% CI: 0.41-0.71) between 2008 and 2015, which is comparable to previous reports. 14-17 Surprisingly, only 35 per cent fulfilled the IPMSSG criteria of ADEM, and none of the children experienced multiphasic ADEM or multiple sclerosis. Nevertheless, two children received disease modifying drugs (interferon beta-1a), despite not fulfilling the IPMSSG criteria for multiple sclerosis. Onethird of the patients with ADEM did not have complete clinical remission after 5 years' follow-up, which illustrates the severe prognosis in ADEM. 4 The strengths of our study are that it is nationwide and population-based and investigates ADEM from the time the IPMSSG criteria were proposed until 2015. The study has a long follow-up of 4 years 6 months. The Danish health care system is publicly financed, which minimizes the risk of selection bias. The NPR is virtually complete because Danish hospital departments are reimbursed based on their patient reporting. Furthermore, all diagnoses were validated by a senior paediatric neurologist with special expertise within demyelinating diseases. A potential weakness is that we evaluated all children through their medical records; therefore, signs of encephalopathy or polyfocal neurological deficits may have been insufficiently described in the chart. Moreover, cases of ADEM erroneously coded in the NPR would not have been included in our data. Finally, it would have been optimal to have had all MRIs reevaluated, but this was not possible in the present study because of logistic and resource limitations.
Our data support the notion that a diagnosis of ADEM in clinical practice is primarily based on MRI findings since virtually all children had an abnormal MRI suggestive of ADEM. Absence of encephalopathy and polyfocal neurological deficits in these patients did not discourage paediatric neurologists from diagnosing ADEM since only 35 per cent of patients with ADEM fulfilled the IPMSSG criteria.
1,9,10 Accordingly, we suggest that the criteria may be overly restrictive. Notably, the subgroup of patients fulfilling the IPMSSG criteria was similar in most clinical and paraclinical aspects except for a younger median age at onset (3y 10mo vs 8y 3mo). Furthermore, we found that only 50 per cent had polyfocal neurological deficits and 71 per cent were encephalopathic at onset in the ADEM cohort investigated. However, it was difficult to precisely define whether the children fulfilled these two clinical features in relation to the IPMSSG criteria for ADEM. This difficulty is likely to arise not only when using medical records, but also in clinical settings. Therefore, the following questions warrant an operational definition for alignment of clinical and research purposes. Firstly, how does one determine whether encephalopathy is not caused by fever, systemic illness, or postictal symptoms when 79 per cent in our cohort presented with fever or infection and 15 per cent had seizures? Secondly, how does one scale when fatigue is sufficiently excessive to be labelled as encephalopathy? Thirdly, how does one define altered behaviour in a child who is sick, when a hallmark of illness is altered behaviour? Additionally, how does one ensure a correct classification of polyfocal neurological deficits in a young child with encephalitis who may be unable to report a slight motor, sensory, or visual disturbance unless this is evident from the neurological examination? Another observation is that more than half our ADEM cases presented with symptoms or MRI abnormalities that can be attributed to the grey matter (seizures or lesions of the basal ganglia). Lastly, should postinfectious demyelinating lesions in the spinal cord in a setting without brain MRI abnormalities be regarded as a subtype of ADEM?
A way to narrow the gap between Clinical ADEM and IPMSSG ADEM could be to introduce a grading system defining 'possible' and 'definite' ADEM. We found that the hallmark of ADEM in clinical practice was white matter lesions on the MRI in a child with recent or current infection, and that the following features encouraged paediatricians to diagnose ADEM: (1) monophasic demyelinating event (judged retrospectively); (2) age at onset under 14 years; (3) recent or current fever/infection; (4) no prior demyelinating events; (5) encephalopathy; (6) presence of neurological symptoms; (7) partial or complete remission of symptoms in the months after ADEM; (8) negative oligoclonal bands and normal immunoglobulin G index; (9) lack of aquaporin-4 antibodies; (10) partial or complete remission of lesions on follow-up MRI; (11) lack of typical multiple sclerosis lesions on the MRI; and (12) other diagnoses unlikely. However, these criteria need validation in prospective studies.
Regarding multiple sclerosis, studies report 5 per cent to 29 per cent of children with ADEM converting to multiple sclerosis, depending on the follow-up time, referral bias, and the definition of ADEM and multiple sclerosis. [2] [3] [4] [5] [6] [7] [8] Several features of ADEM have been found to be associated with an increased risk of progression to multiple sclerosis such as: non-encephalopathic onset, optic neuritis, seizures, family history notable for central nervous system demyelination, presence of T1-hypointense and T2-periventricular lesions, and oligoclonal bands. 6, 7, 18 We could not corroborate these findings since none of the children with ADEM in our cohort progressed to multiple sclerosis with a median follow-up of 4 years 6 months. Our findings speak against the notion that ADEM is a common onset symptom in paediatric multiple sclerosis as the ADEM incidence peaks in 2-and 3-year-olds and the youngest child with multiple sclerosis in Denmark since 1977 presented at 7 years of age. 19 In the ADEM cohort investigated, the mean age at onset was 7 years 2 months, which is comparable to previous studies. [4] [5] [6] 14 However, at the end of follow-up the median age remained at 10 years 9 months and multiple sclerosis is extremely rare at this age. 19 We plan to evaluate these factors in future studies of our ADEM cohort in age-groups with higher multiple sclerosis incidence.
As we did not find children progressing from ADEM to multiple sclerosis, we suggest that more than two followup MRIs have limited value unless there is a clinical relapse. However, long-term clinical follow-up is crucial because of the risk of other neurological sequelae from ADEM. Future research should test whether encephalopathy, polyfocal neurological deficits, recent or current infection, or biomarkers, such as myelin oligodendrocyte glycoprotein or aquaporin-4 antibodies, in paediatric ADEM are negative predictors of multiple sclerosis or can be used to stratify prognosis and therapy.
